An Open Label, Prospective, Randomised, Comparative, Two Arm Clinical Study to Evaluate the Effectiveness of Gaming Platform Ã¢â?¬â?? COSMA Software from Cerebrum Matter Ltd. in Adults with Mild NeuroCognitive Impairment, Vascular Dementia and/or Dementia Associated with AlzheimerÃ¢â?¬â?¢s Disease.

Cerebrum Matter Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Verified neurological evaluation and diagnosis of Mild NeuroCognitive Impairment, Vascular Dementia and/or Dementia associated with AlzheimerÃ¢â?¬•s Disease
•2.Neurocognitive evaluation with Functional Assessment Staging Test : Stage 3 to Stage 5
•3.Male and female adults less than 65 years of age
•4.Subjects who are classified as right handed
•5.Subjects who can read and write Tamil and/or English
•6.Subjects who can use the provided Android Tablet
•7.Subjects with a dedicated LAR or caretaker to address any study objectives in lieu of the subject.
•8.Subject/LAR who is willing to give informed consent for participation, able to comprehend and understand the responsibilities during treatment period and follow up period.

•1.Subjects with mental illness and/or neuropsychiatric disorders.
•2.Subjects who are on anti-depressants, anti-psychotics and/or medication that may cause worsening in cognitive functions.
•3.Subjects with significant primary visual impairments.
•4.Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.), any medical condition that is unstable/poorly controlled or other factor (e.g., planned relocation) that the Investigator felt would interfere with study evaluations and study participation.
•5.Subjects who have participated in any clinical study within 3 months from the date of enrolment.
•6.Females who are pregnant or lactating or planning to become pregnant or unwilling to use double barrier method during the study period.
•7.Subjects who mentally unable to comprehend the responsibilities and adhere to the stipulations of the protocol.
•8.Subjects, who in the opinion of the Investigator/CRMC are not eligible for enrolment in the study.

发起方

Cerebrum Matter Limited